A nested case control study for risk factors impacting hepatitis B vaccination in Hebei, China / 中华实验和临床病毒学杂志

<p><b>OBJECTIVE</b>Study the risk factors that impact the effectiveness of mass hepatitis B vaccination, and try to amend them in the future.</p><p><b>METHOD</b>Based on the national surveillance of hepatitis B, all the 1734 of 1-15 years old children from Hebei Province were enrolled in the present study and they were divided into case and control group according to their sera HBsAg were positive or not.</p><p><b>RESULTS</b>Mother sera HBsAg positive and the hospital the children were born and earlier year of birth were risk factors.</p><p><b>CONCLUSION</b>The effectiveness of mass neonate hepatitis B vaccination has greatly improved and the future focus should be on finding pregnant HBsAg positive women, and encourage them to give birth in better hospitals, and at the mean time, try to make the neonate hepatitis B vaccination perfect, especially in country areas.</p>

Safety and immunogenicity of Bilive combined hepatitis A and B vaccine / 中华流行病学杂志

<p><b>OBJECTIVE</b>To study the safety and immunogenicity of the Bilive combined hepatitis A and B vaccine produced by Sinovac Biotech Co., Ltd.</p><p><b>METHODS</b>Samples were selected from first year students of a senior high school (adults group) and first to fifth grade 1-5 students of 3 primary schools (children group). Those who were susceptible to both hepatitis A virus (HAV) and hepatitis B virus (HBV), HAV only or HBV only were assigned to group AB, A and B respectively and were vaccinated with three doses (0, 1 and 6 month schedule) of Bilive combined hepatitis A and B vaccine, inactivated hepatitis A vaccine and recombined hepatitis B vaccine respectively. The dosage for adult group was 500 U hepatitis A antigen and/or 10 micro g hepatitis B surface antigen and the dosage for children group was half the dosage of adult group. The potential adverse effects were observed within 72 hours after vaccination. Serum samples were collected for testing anti-HAV and anti-HBs at month 2 and 7 after the initial dose.</p><p><b>RESULTS</b>The rates of local adverse effects were 0.58% and 2.56% in children AB group and adults AB group and the general adverse effects rates were 9.88% and 5.45% respectively. Both local and general adverse effect rates were not significantly different to the control group. The sero-conversion rate of anti-HAV in children and adults AB group reached 100%, one month after 3 doses. The geometric mean titer (GMTs) reached 33,910 mIU/ml and 23,435 mIU/ml respectively, significant higher than that in control group (group A). The sero-conversion rates of anti-HBs were 97.30% and 96.63%, and GMTs were 103 mIU/ml and 102 mIU/ml in children and adults AB group respectively. No significant difference on sero-conversion and GMT was observed when compared with control group.</p><p><b>CONCLUSION</b>The Bilive combined hepatitis A and B vaccine had good safety profile, and the immunogenicity both on anti-HAV and anti-HBs was similar to that of separated components.</p>

Investigation of etiology and prognosis of the hospitalized patients with chronic obstructive pulmonary disease during acute exacerbation / 中国实用内科杂志

0.05).The concentration of IL-6 in sputum of multi-virus infection group(122.51?39.86)ng/L was higher than in single virus infection group(65.30?34.92)ng/L.The concentration of IL-6 in sputum of bacteria-virus mixed infection group(120.31?46.62)ng/L was higher than in bacteria or virus single infection group(83.61?47.83)ng/L.Conclusion Streptococcus pneumonia and influenza virus A infection are important factors in AECOPD at early stage.Virus infection would prolong recovery time,increase inflammation of the airway and even induce bacteria infection.Therefore,we should pay more attention to the virus infection in COPD patients,especially A-type influenza virus.